



**HAL**  
open science

## Mapping the molecular motions of 5-HT<sub>3</sub> serotonin-gated channel by Voltage-Clamp Fluorometry

Laurie Peverini, Sophie Shi, Karima Medjebeur, Pierre-Jean Corringer

► **To cite this version:**

Laurie Peverini, Sophie Shi, Karima Medjebeur, Pierre-Jean Corringer. Mapping the molecular motions of 5-HT<sub>3</sub> serotonin-gated channel by Voltage-Clamp Fluorometry. *eLife*, 2024, 12, pp.RP9317. 10.7554/eLife.93174 . pasteur-04782136

**HAL Id: pasteur-04782136**

**<https://pasteur.hal.science/pasteur-04782136v1>**

Submitted on 14 Nov 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

# **Mapping the molecular motions of 5-HT<sub>3</sub> serotonin-gated channel by Voltage-Clamp Fluorometry**

Laurie Peverini<sup>1,\*</sup>, Sophie Shi<sup>1</sup>, Karima Medjebeur<sup>1</sup>, Pierre-Jean Corringer<sup>1,\*</sup>.

<sup>1</sup>Institut Pasteur, Université Paris Cité, CNRS UMR 3571, Channel-Receptors Unit, Paris, France

Corresponding authors : \*Laurie Peverini ; \*Pierre-Jean Corringer

**Email** : laurie\_peverini@hotmail.com; pierre-jean.corringer@pasteur.fr

**Author Contributions:** L.P. set up and performed VCF, TEVC and mutagenesis. S.S. performed some TEVC and VCF experiments. K.M. performed some mutagenesis. L.P. and P.-J.C. designed the study. L.P. and S.S. analyzed the data. L.P. and P.-J.C. wrote the manuscript. P.-J.C. acquired funding.

**Competing Interest Statement:** The authors declare no competing interests.

**Classification:** Biological Sciences, Neuroscience.

**Keywords:** 5-HT<sub>3A</sub>; Voltage-Clamp fluorometry; pLGICs; molecular motions; orthosteric ligands

**This PDF file includes:**

Main Text  
Figures 1 to 4  
Tables 1 to 2

## Abstract

The serotonin-gated ion channel (5-HT<sub>3</sub>R) mediates excitatory neuronal communication in the gut and the brain. It is the target for setrons, a class of competitive antagonists widely used as antiemetics, and is involved in several neurological diseases. Cryo-electron microscopy of the 5-HT<sub>3</sub>R in complex with serotonin or setrons revealed that the protein has access to a wide conformational landscape. However, assigning known high-resolution structures to actual states contributing to the physiological response remains a challenge.

In the present study, we used voltage-clamp fluorometry (VCF) to measure simultaneously, for 5-HT<sub>3</sub>R expressed at a cell membrane, conformational changes by fluorescence and channel opening by electrophysiology. Four positions identified by mutational screening report motions around and outside the serotonin-binding site through incorporation of cysteine-tethered rhodamine dyes with or without a nearby quenching tryptophan. VCF recordings show that the 5-HT<sub>3</sub>R has access to four families of conformations endowed with distinct fluorescence signatures: “resting-like” without ligand, “inhibited-like” with setrons, “pre-active-like” with partial agonists and “active-like” (open channel) with partial and strong agonists. Data are remarkably consistent with cryo-EM structures, the fluorescence partners matching respectively Apo, setron-bound, 5-HT bound-closed and 5-HT-bound-open conformations. Data show that strong agonists promote a concerted motion of all fluorescently labelled sensors during activation, while partial agonists, especially when loss-of-function mutations are engineered, stabilize both active and pre-active conformations.

In conclusion, VCF, though the monitoring of electrophysiologically silent conformational changes, illuminates allosteric mechanisms contributing to signal transduction and their differential regulation by important classes of physiological and clinical effectors.

## Significance Statement

High-resolution structures of serotonin-gated receptors (5-HT<sub>3A</sub>R) have evidenced a wide range of conformations that are challenging to annotate to physiologically relevant states. Voltage-clamp fluorometry allows to investigate the activation of 5-HT<sub>3A</sub>R by simultaneously following molecular motions and electrophysiological states at the plasma membrane. Here, we developed four fluorescent sensors reporting conformational changes at the serotonin binding site and at the extracellular domain and transmembrane domain interface. Investigation of a series of agonists, partial agonists and antagonists show that strong agonists promote a concerted motion of the whole protein during activation, while antagonists and partial agonists stabilize distinct closed-channel conformations. Data offer insights into allosteric mechanisms, unravelling the conformational dynamics of the receptors and helping to annotate high-resolution static structures.

## Main Text

### Introduction

Pentameric ligand-gated ion channels (pLGICs), comprising nicotinic acetylcholine (nAChRs), serotonin (5-HT<sub>3</sub>Rs), glycine (GlyRs) and gamma-aminobutyric acid (GABA<sub>A</sub>Rs) receptors are dynamic transmembrane proteins that mediate neuronal and non-neuronal communication (1). Among them, 5-HT<sub>3</sub>Rs are cation-selective excitatory channels expressed in central and peripheral nervous systems, notably in the gut and gut-brain axis (2). 5-HT<sub>3</sub>Rs are encoded by five different genes (*HTR3A*, *HTR3B*, *HTR3C*, *HTR3D*, *HTR3E*), giving rise to five different subunits (A to E) that assemble as homo- or hetero-pentamers. A class of synthetic competitive antagonists called setrons target these receptors and are widely used in the clinic as antiemetics, notably to counteract vomiting and nausea induced by chemotherapy and radiotherapy. 5-HT<sub>3</sub>Rs are also potential targets to treat irritable bowel syndrome and are implicated in neurological diseases such as schizophrenia, Parkinson's disease, and depression. There is therefore much interest surrounding the molecular mechanisms governing 5-HT<sub>3</sub>R function and pharmacological regulation (3–5).

A hallmark of pLGICs, and among them 5-HT<sub>3</sub>R, is that their action is mediated by varying population equilibrium between allosteric states that are differentially stabilized by the binding of ligands (6,7). Agonists promote the allosteric transition between resting (closed channel) and active (open channel) states, while their prolonged application promotes a slower transition to desensitized (agonist-bound closed channel) conformations.

The first high-resolution structure of mouse homo-pentameric 5-HT<sub>3A</sub>R was solved by X-ray crystallography in complex with stabilizing nanobodies, followed by numerous structures solved by Cryo-Electron Microscopy (Cryo-EM) without ligands or in complex with the agonist 5-HT, a series of setron competitive antagonists and an allosteric modulator (8–15). The 5-HT<sub>3A</sub>R displays a typical pLGIC structure, where each subunit consists of a  $\beta$ -sandwich connected with loops composing the extracellular domain (ECD), 4  $\alpha$ -helices composing the transmembrane domain (TMD) and an intracellular domain. Agonists and competitive antagonists bind at the ECD interface between two subunits, at the orthosteric site composed of so-called loops A, B and C from the principal subunit and D, E and F from the complementary subunit, with loop C bridging the subunit interface. In the presence of detergent C12E9 with or without added lipids, or in saposin nanodiscs, solved structures in the absence of orthosteric ligand (Apo) were assigned as resting-like (8,10,15). Those in complex with setrons significantly diverged from the resting-like class and were called inhibited states (9,12–14). The structures captured with bound 5-HT all feature rather similar motions of the ECD, with 5-HT binding promoting a closure (in a capping motion) of loop C around the agonist, a global compaction, and a tilt of each subunit ECD. This generates a marked reorganization of the ECD-TMD interface, including in some cases an outward motion of the M2-M3 loop. However, the structures strongly diverge in the TMD, some featuring an apparently open pore and others a non-conducting pore (9,11). In addition, reconstitution into saposin-based nanodiscs captured distinct open conformations with symmetrical or asymmetrical conformation of the TMD (15). Therefore, these atomic structures led to a complex landscape of more than the three putative conformations (resting, active, desensitized). Furthermore, 5-HT<sub>3</sub>R's wide conformational landscape accessibility seems to be governed by both orthosteric effectors and the lipids and/or detergents surrounding the TMD. Assigning these high-resolution structures to actual

physiological states contributing to the electrophysiological response at the cell membrane remains to be established (16).

Complementary techniques that follow the structural reorganizations of the cell-expressed receptors are thus needed to identify structural motions contributing to gating (i.e., the pathway between resting and activated/open) and to help annotate high-resolution structures to physiologically-relevant conformational states (16). Voltage-clamp fluorometry (VCF), which monitors receptors expressed at the *Xenopus* oocyte plasma membrane, is well suited for this aim. VCF performs simultaneous measurement of channel opening by two-electrode voltage-clamp electrophysiology (TEVC) and of local protein motions by variation of fluorescence from covalently attached probes (17). This technique has been applied to various pLGICs, notably to human 5-HT<sub>3A</sub>R with the generation of three sensors surrounding the orthosteric site as well as one sensor on the mouse 5-HT<sub>3A</sub>R located at the extracellular entrance of the pore (9,18).

In the present study, we have generated four fluorescent sensors grafted at new locations on the mouse 5-HT<sub>3A</sub>R. We characterized their phenotypes following the binding of various agonists, partial agonists and clinically relevant antagonists, with or without introduction of loss-of-function mutations. Simultaneous recordings of electrical currents and variations of fluorescence revealed different local and global reorganizations of the ECD depending on the pharmacological conditions. By following the conformational reorganizations leading to both electrophysiologically silent and active conformations, VCF data identify intermediate conformations within or outside the path of 5-HT<sub>3</sub>R activation. These data provide unique structural information on membrane-embedded proteins to annotate known high-resolution structures to physiologically relevant allosteric states.

## Results

### 1) Generation of four fluorescent sensors along the ECD.

To guide the design of fluorescent sensors, we inspected the regions undergoing the largest reorganizations in the various Cryo-EM structures, mainly mapping the subunit interface from the apex of the ECD to the ECD-TMD interface and the upper part of the TMD. We introduced cysteines by mutagenesis and covalently labelled them with the fluorescent probe MTS-TAMRA, allowing conjugation of a rhodamine dye with the protein main chain through a flexible 6-atom linker (CH<sub>2</sub>-S-S-CH<sub>2</sub>-NH-CO). Since rhodamine fluorescence is sensitive to its local molecular environment, this generates conformational sensors around the graft position (18). In order to increase the intensity of fluorescent variations and to report more precisely the motion observed, we also implemented the tryptophan-induced quenching method (19) (Figure 1.A.). In this technique, the cysteine-labeled rhodamine is introduced together with a nearby tryptophan, since the indole moiety of the Trp side chain robustly quenches rhodamine fluorescence when in Van der Waals contact. Such pairs sense the distance between the fluorophore and indol attachment points and/or local environment, and often amplify the extent of the fluorescence variation when allosteric motions are associated with structural reorganization at this level (39).

Nineteen TAMRA-labelled cysteine mutants were screened by VCF under perfusion of high concentration of 5-HT (Figure 1. A). We verified that the mouse wild-type 5-HT<sub>3</sub>R (m5-HT<sub>3</sub>R), that does not carry any single cysteine within the ECD, yielded robust 5-HT-elicited currents upon

treatment with MTS-TAMRA but no changes in fluorescence intensity. The screening allowed for the selection of four mutants (one cysteine and three cysteine/tryptophan pairs) endowed with robust variations of both current and fluorescence.

We first identified the single mutation S204C, which is located near the tip of loop C, facing the adjacent subunit and the ECD interface above the orthosteric site (Fig 1.B). Second, three fluorophore/quencher (cysteine/tryptophan) pairs were selected. In each case, the measured 5-HT-elicited variation of fluorescence ( $\Delta F$ ) was much smaller or unmeasurable when the cysteine but not the tryptophan was introduced, indicating that the dequenching or quenching observed is dominated by Van der Waals interaction between the rhodamine dye and the indole of the tryptophan (Figure S1.C.). The pairs are the following:

1) I160C/Y207W: I160C is located in close proximity to the orthosteric site but outside the pocket behind the base of loop C, while Y207W lies inside the pocket nearby bound ligands in agonist and antagonist co-structures. Of note, the aromatic side chain of Y207 contributes to the binding and gating in 5-HT<sub>3</sub>R, with a strong effect of alanine and serine mutations, but comparatively weaker effect of phenylalanine or unnatural aromatic mutations (20). The pair is located away from the subunit interface thus reporting tertiary reorganizations (Fig 1.C).

2) V106C/L131W: V106C is facing the vestibule of the ECD, a large water-accessible channel with several constrictions and ring of charges that lies above the TMD ion channel. L131W is positioned more profoundly in each ECD, its side chain remaining visually accessible through the vestibule. Given the proximity of all subunits in this confined space, the observed fluorescence variation can potentially arise from quenching by tryptophan of any of the five subunits (Fig 1.D). Of note, we verified that the observed fluorescent quenching is not caused by direct collisional quenching with the hydroxy indole group of perfused 5-HT, that arises at concentrations above 200  $\mu$ M (see an example of direct quenching by 5-HT perfused at 1000  $\mu$ M, Figure S1.C.).

3) R219C/Y140W are positioned at the ECD/TMD interface. R219C is located in the pre-M1 area and Y140W in the highly conserved Cys-loop. Both positions flank the M2-M3 loop that undergoes a major outward motion in some agonist-bound structures (Fig 1.E).

## **2) The four sensors monitor fast motions not related to desensitization**

The four sensors were recorded on a custom VCF chamber where the ligands are perfused only on the portion of the oocyte from which the fluorescence emission is collected (21). This ensures that the same population of receptors is recorded in current and fluorescence simultaneously. For all sensors, perfusion of a high concentration of strong agonists (5-HT or mCPBG, selected depending on the particular sensor, see dedicated section to each sensor) elicit currents reaching maximal value in a few seconds, followed by desensitization appearing with much slower kinetics (Fig 1.G). To measure the desensitization kinetics, we performed parallel measurements on a dedicated TEVC setup equipped with a fast perfusion system allowing solution exchange in less than a hundred milliseconds (22). This shows that all sensors display comparable desensitization kinetics to that of the wild-type receptor (WT), evaluated in the 50-150  $s^{-1}$  range though mono-exponential fitting (Fig S2). Thus, activation and desensitization appear well separated in time in the VCF setup. This allows a reasonable evaluation of the extent of activation by measuring the amplitude of the peak current. Concentration-response curves measured at this peak current show that, for all sensors, labelling by MTS-TAMRA has no significant effect in terms of EC<sub>50</sub> current (EC<sub>50c</sub>) (Fig S1.B).

In fluorescence, labelled S204C, I160C/Y207W and R219C/Y140W show robust agonist-elicited dequenching and V106C/L131W agonist-elicited quenching. In all cases, the rise-time of

the fluorescence variations ( $\Delta F$ s) are in the same range to that of the rise-time of the currents (1-10 s<sup>-1</sup> range depending on the particular sensor and the agonist concentration, Table S1). In contrast, prolonged applications of agonist show no significant variation of the fluorescence during the desensitization phase (with the fluorescent signal remaining stable), providing evidence that the sensors do not report movements related to desensitization (Fig 1.G). As far as the four sensors are concerned, VCF data suggest that the ECD (and its labels) does not undergo notable conformational changes between activated and desensitized states.

### **3) Competitive antagonists elicit agonist-like reorganizations at the orthosteric site that do not spread to the lower part of the ECD**

We first explored the action of competitive antagonists on the various sensors. To this end, we applied to the same oocyte saturating concentrations of the agonists 5-HT, mCPBG (*m*-chlorophenylbiguanide) and var (varenicline) as well as a selection of four competitive antagonists of different molecular structure: alosetron, granisetron, ondansetron and metoclopramide (23,24). We used a 3  $\mu$ M concentration of each antagonist, which is far above their nanomolar binding affinities measured on the WT receptor.

On the two sensors neighboring the orthosteric site, antagonists produce no current, but robust  $\Delta F$ s are observed in the same direction as agonists do (Fig 2.A and 2.C). In addition, the amplitude of  $\Delta F$ s evoked by antagonists are in the same range than that of agonists for granisetron and ondansetron while it is significantly higher for alosetron and lower for metoclopramide. This suggests that, locally, antagonists elicit similar reorganizations as agonists do but with various amplitudes (Figure 2.A. and 2.C. left panels).

In contrast, the sensors at the vestibular site (V106C/L131W) and at the ECD-TMD interface (R219C/Y140W) show no antagonist-elicited current nor  $\Delta F$ , suggesting that the conformational effects elicited by these competitive antagonists do not spread to the vestibule and lower part of the ECD (Fig 3.A. and 3.C, left panels).

### **4) Correlation between the orthosteric site motions and ion channel activation.**

The sensor S204C displays electrophysiological properties identical to that of the WT, both in terms of agonist potency and efficacy. EC<sub>50c</sub> are identical between S204C and WT, i.e. 1.8 and 1.8  $\mu$ M for 5-HT, 1.4 and 1.1  $\mu$ M for mCPBG, and 20.6 and 21.1  $\mu$ M for var, respectively (Table 2). mCPBG appears as a near full agonist, eliciting 89% and 92% of maximal 5-HT currents on S204C and WT, respectively, while var appears as a partial agonist eliciting only 33% and 39% of maximal 5-HT currents on S204C and WT, respectively (Table 1). All data on WT are consistent with TEVC data reported in the literature (24).

The strong agonists 5-HT and mCPBG elicit similar maximum fluorescence variation ( $\Delta F_{max}$ ) at saturation. Concentration-response curves show that the variations of current ( $\Delta I$ s) and fluorescence are well correlated with similar EC<sub>50</sub> fluorescence (EC<sub>50f</sub>) and EC<sub>50c</sub>. This shows that agonists promote local reorganizations around the binding site that are correlated to the opening of the channel, suggesting a concerted motion of the orthosteric site and the ion channel during activation. As for strong agonists, var displays similar EC<sub>50f</sub> and EC<sub>50c</sub>. However, it displays a  $\Delta F_{max}$  similar to that of strong agonists despite activating only 33% of the current. Therefore, var at saturation promotes full reorganization of the binding site suggesting that among the population displaying a variation of fluorescence, only a fraction shows an open channel (Fig 2.A).



To further investigate the S204C sensor on a different allosteric background, we introduced the strong loss-of function mutation N101K. Substitution of N101 by several natural or unnatural amino acids indeed produces a marked increase in agonist  $EC_{50}$  (25,26). N101 is located just below the orthosteric site on loop A and has been proposed to contribute to the allosteric network coupling the orthosteric site to the ion channel. In combination with S204C, N101K displays, as expected, a loss-of-function phenotype characterized by : 1/ a 31-fold and 9-fold increase in  $EC_{50C}$  for 5-HT and mCPBG, respectively, 2/ a decreasing efficacy of 5-HT as compared to mCPBG, as already reported and 3/ a decreasing efficacy of var yielding no detectable current (Fig 2.B and Tables 1 and 2). Interestingly, the effects on the fluorescence variations were comparatively weaker, N101K causing only a 4-fold and a 1.4-fold increase in  $EC_{50f}$  for 5-HT and mCPBG, respectively, while var causes a  $\Delta F$  higher than 5-HT at saturation (173%, figure 2.B. left panel and Table 1) with a 1.6-fold increase in  $EC_{50f}$  (Table 2 and Figure 2.B.). Therefore, N101K on S204C decorrelates the  $\Delta F$  and  $\Delta I$ . For 5-HT and mCPBG,  $\Delta F$ s are already robust at agonists concentrations not eliciting sizable currents (for instance at 5  $\mu M$  5-HT and 1  $\mu M$  mCPBG, see Figure 2.B.). For var, it elicits quantitative  $\Delta F$  but no current.

Finally, the sensor I160C/Y207W displays by itself a marked loss-of-function phenotype characterized by: 1/ a 7-fold and 17-fold increase in  $EC_{50C}$  for mCPBG and 5-HT as compared to the WT, respectively (Table 2) and 2/ at saturation, mCPBG is the most efficient agonist, while 5-HT elicits only 2 % of its currents and var fails to activate the channel (Table 1, Fig 2.C. left panel). Of note, this phenotype is caused by both I160C and Y207W mutations, that individually cause a 17-fold and 12-fold increase in the  $EC_{50C}$  for 5-HT, respectively (Fig S1.A. right panel). Given the position of these mutations within and around the orthosteric site, their effect is likely due to a mix of alteration of both gating and binding affinity of the agonists. The phenotype of I160C/Y207W resembles that of S204C/N101K, with a leftward shift of the  $\Delta F$  over the  $\Delta I$  curve for the partial agonist 5-HT, and robust  $\Delta F$  but no  $\Delta I$  for var (Fig 2.C).

Altogether, VCF data obtained for these two sensors close to the binding site highlight three families of conformations, the apo conformations, the agonist-bound active conformations characterized by a concerted reorganization of the orthosteric site, and the ion channel (opening) and ligand-bound intermediate conformations characterized by reorganization of the orthosteric site with a closed channel. On the S204C that displays a WT-like phenotype, these intermediate conformations are partially populated for the partial agonist var. On the two loss-of-function backgrounds (S204C/N101K and I160C/Y207W), these intermediates are fully stabilized by var that behaves as an antagonist and are partially populated for 5-HT and mCPBG at sub-saturating concentrations.

## **5) Correlation between vestibular and ECD-TMD interface motions and ion channel activation.**

VCF recordings of both V106C/L131W and R219C/Y140W sensors show reproducible currents upon mCPBG perfusion at saturation but not in the case of long recordings required for dose-response curves, where they were non-reproducible. In contrast, 5-HT and var elicit robust and reproducible currents endowed with moderately faster apparent desensitization as compared to orthosteric sensors (illustrated by the current traces in Fig 3 and Fig S2). For both sensors, quantification of the desensitization kinetics on the fast-perfusion TEVC setup confirms a slight

increase in desensitization kinetics for 5-HT and var but shows surprisingly very fast desensitization kinetics for mCPBG. This explains why, in the VCF setup endowed with a relatively slow perfusion system, the very transient mCPBG-elicited activation peak is truncated by desensitization, precluding its further analysis.

V106C/L131W and R219C/Y140W both display a gain-of-function phenotype that is moderate for the former (1.5-fold and 2.7-fold decrease  $EC_{50c}$  for 5-HT and var, respectively), and more pronounced for the latter (5.5-fold and 22.5-fold decrease  $EC_{50c}$  for 5-HT and var, respectively). For both sensors, var appears as a partial agonist eliciting around 30% of the 5-HT currents (Fig 3.A, 3.C and Table 1). We also combined R219C/Y140W with the loss-of function N101K mutation. N101K reverts the R219C/Y140W gain-of-function phenotype, the triple mutant R219C/Y140W/N101K displaying  $EC_{50c}$  of 5-HT and var close to that of the WT (Fig 3.B).

These three sensors show a good correlation between  $EC_{50c}$  and  $EC_{50f}$  for the strong agonist 5-HT, suggesting that the motions reported by fluorescence at the vestibule and ECD-TMD interface are concerted with channel opening. For the partial agonist var on V106C/L131W and R219C/Y140W, the  $\Delta F_{max}$  (40-50% of that of 5-HT) is comparable to the  $\Delta I_{max}$  (30-40% of that of 5-HT), suggesting in the first approximation that var at saturation promotes the same transition as 5-HT, but only partially. However, concentration-response curves on V106C/L131W show a small yet visible decorrelation of fluorescence and current, suggesting the occurrence of intermediate conformations. R219C/Y140W/N101K confirms this idea with var. On this construct, var acts as a strongly partial agonist eliciting at saturation only 3% of the 5-HT currents, while it displays 37% of the  $\Delta F$  evoked by 5-HT (Fig 3.B. left panel). In addition, var shows a leftward shift of the fluorescence dose-response curve as compared to the current dose response curve (with  $EC_{50c}$  being 15.6  $\mu M$  and  $EC_{50f}$  is 5.2  $\mu M$ ) (Fig 2.B, right panel).

In conclusion, as for orthosteric-located sensors, fluorescent and current signals are well correlated for strong agonists, pointing to a concerted mechanism. In contrast, the partial agonist var on V106C/L131W and especially on R219C/Y140W/N101K shows a decorrelation of fluorescence and current, pointing to the contribution of distinct states endowed with robust  $\Delta F$  but no  $\Delta I$ .

## Discussion

In this work, we undertook a screening of 19 mutants of the m5-HT<sub>3A</sub>R with an aim to identify fluorescent sensors within the ECD. Around the orthosteric site, we find that cysteine incorporation often yields  $\Delta F$  suitable for VCF investigation. In contrast, outside the orthosteric site all single-cysteine mutants investigated failed. This observation parallels a previous VCF screening on the h5-HT<sub>3A</sub>R that identified four suitable sensors around the orthosteric site but none among the seven additional positions tested in the pre-M1 region (18). Of note, we have previously investigated a sensor on the top of M2 helices on m5-HT<sub>3A</sub>R (9). In the pLGIC family, the  $\alpha$ 1-GlyR has also been extensively studied by VCF and many positions were screened for cysteine incorporation (21,27–30). In contrast to the 5-HT<sub>3</sub>R, most positions show robust  $\Delta F$  outside the orthosteric site. This suggests that the  $\alpha$ 1-GlyR undergoes gating reorganizations of larger amplitude than that of the 5-HT<sub>3</sub>R. Still, we succeeded in designing two sensors at the vestibule and the ECD-TMD interface by implementing the tryptophan-induced quenching method, further illustrating that this technique is suitable to monitor subtle conformational changes when the fluorophore-quencher pair is properly engineered.

The mapping of the 5HT<sub>3</sub>R has enabled us to generate four fluorescence sensors of the protein conformations. They are located at three distant positions within the ECD 3D structure, thereby constituting reference points to infer its global conformation. Simultaneous steady-state concentration-response relationships for the fluorescence and current responses reveal important ligand-elicited protein motions and their relationship with activation.

We first show that agonists and antagonists elicit similar local reorganizations around orthosteric sensors. For both S204C and I160C/Y207W, all tested ligands at saturating concentrations elicit fluorescent dequenching signals. All agonists, partial agonists, granisetron and ondansetron elicit  $\Delta F$  of similar amplitude, while alosetron compared to metoclopramide display significantly higher and lower  $\Delta F$ , respectively. These results are in remarkable concordance with Cryo-EM structures. They show that both 5-HT and a series of setron antagonists promote locally a similar reorganization of the orthosteric site, with an inward displacement of the landmark loop C that caps the bound ligand (Fig S3) (9,11). Furthermore, subjecting these structures to molecular dynamic simulations suggests that different antagonists promote different degrees of local conformational changes (12,13). Among setrons, alosetron is the one promoting the largest conformational effects, consistent with VCF data. Of note, the ligand-elicited dequenching signal of the I160C/Y207W is also consistent with the Cryo-EM structures, since the capping of loop C is predicted to reduce the accessibility of the indole side chain to the rhodamine dye grafted on the other side of the loop. Interestingly, three other fluorescence sensors around the orthosteric site were already reported on the human 5-HT<sub>3A</sub>R on loop C (M223C), D (Y89C) and E (Q146C). They also report that agonists and antagonists equally elicit fluorescence dequenching, with  $\Delta F$  intensities strongly ligand-dependent for loop C and E, but not for loop D (18).

We also show that antagonist-elicited reorganizations do not spread to the vestibular and ECD-TMD sensors. Indeed, the sensors at the ECD-TMD interface (R219C/Y140W) and at the middle vestibule (V106C/L131W) show robust  $\Delta F$  upon perfusion of agonists, but no effect for antagonists. Cryo-EM structures show no setron-elicited change at the ECD-TMD interface, especially no motion of the M2-M3 loop that lies in between the attachment points of the fluorophore and the indole of the tryptophan in R219C/Y140W (Fig S3) (9,13,14). Likewise, setrons elicit small reorganizations of the architecture of the vestibule (measured as a slightly increased radius of the constriction at K108 and D105), while 5-HT elicits stronger reorganizations at this level. Overall, VCF data are in excellent agreement with Cryo-EM data, providing evidence that high resolution structures of setron-inhibited states represent pertinent snapshots of actual allosteric states at the plasma membrane.

Steady-state concentration-response relationships support that strong agonists elicit an apparently concerted reorganization of the global protein structure. Indeed, for most constructs, those agonists eliciting the maximal response currents amongst all tested agonists show no difference in  $\Delta F$  and  $\Delta I$  concentration-response curves. This is the case for 5-HT, that maximally activates the S204C, V106C/L131W and R219C/Y140W sensors and for mCPBG that maximally activates the S204C and I160C/Y207W sensors. This suggests a concerted mechanism where local motions around the four sensors happen simultaneously with the pore opening. These data are thus accounted by a simple two-state model, where the receptor is in equilibrium between a resting and an active state. VCF measurements are also remarkably coherent with the 5HT-bound structures showing an open pore: PDB 6HIN (called F), PDB 6DG8 (called State 2) and PDB Y5A (called serotonin-bound

state). Indeed, all of them show symmetrical and global reorganizations of the ECD involving loop C capping, vestibular reorganization and M2-M3 reorganization (Fig S3) (9,11,15).

However, we found that partial agonists stabilize additional intermediate conformations characterized by fluorescence variations but no current, especially when loss-of-function mutations are engineered. Intermediate conformations are observed for the two sensors outside the orthosteric site. Indeed, for R219C/Y140W sensor in combination with N101K, var elicits at saturation only 3% of 5-HT currents but promotes a robust  $\Delta F$  signal corresponding to 38% of that of 5-HT. In addition, the  $\Delta F$  concentration-response curve appears slightly left-shifted as compared to the  $\Delta I$  curve, indicating that the  $\Delta F/\Delta I$  ratio is even higher at low var concentrations. These data clearly show that var stabilizes in majority intermediate conformations where the ECD-TMD interface has moved, generating a  $\Delta F$ , but where the channel remains closed. A similar although milder “intermediate” phenotype is seen for var on the V106C/L131W sensor.

Within the gating pathway, these intermediate conformations may *a priori* contribute either to the activation transition (pre-active state) or to the desensitization transition (fast or slow desensitized states). However, VCF data strongly argue for the former hypothesis. Indeed, for all experiments including var partial activation of V106C/L131W, the rise-times of  $\Delta F$  are in the same range to that of  $\Delta I$ , desensitization being much slower and associated with no significant  $\Delta F$ . This shows that the intermediate states are recruited during or concomitant with the activation phase. This is in line with the general observation that partial agonists currents are strongly increased by positive allosteric modulators, indicating that the electrophysiologically silent conformations they promote are activatable and therefore not desensitized (31).

Two 5-HT-bound structures of m5-HT<sub>3A</sub> displaying a closed channel sustain the intermediate reorganizations seen by VCF. Indeed, conformations called I1 (PDB 6HIO) and State 1 (PDB 6DG7) feature rearrangements at the ECD and interface between ECD/TMD similar to that of conformation displaying an open channel, but with non-conducting pore (Fig S3) (9,11). It is noteworthy that these states were initially proposed to represent either pre-active or desensitized states, and that these two possibilities could not be distinguished without ambiguity. However, indirect experiments of substituted cysteine accessibility method (SCAM) experiments suggested that desensitization involves weak reorganizations of the upper part of the channel that holds the activation gate, arguing for the pre-active state hypothesis (9). Combined SCAM and VCF data thus provide compelling evidence for annotation as pre-active state. Finally, during the revision of this article, several cryo-EM structures of m5-HT<sub>3A</sub> in complex with partial agonists SMP-100 and ALB-148471 were published. In full agreement with our VCF data, partial agonists are found to stabilize the protein in both active and pre-active-like conformation (31).

Intermediate conformations are also observed on many occasions for the sensors near the orthosteric site. This is the case with the var partial agonist on S204C, which produces a lower maximum current variation ( $\Delta I_{max}$ ) than that caused by 5-HT but a higher  $\Delta F_{max}$ . The phenotype is exacerbated in the presence of N101K, 5-HT and mCPBG showing intermediate conformations at sub-saturating concentrations, while varenicline promote no current while still evoking robust  $\Delta F$ . Of note, on this mutant, mCPBG is the most efficient agonist, but it remains possible that it has a partial agonistic character due to the strong loss-of-function N101K mutation. In this context, the sensor I160C/Y207W shows a loss-of-function phenotype resembling that of S204C/N101K with comparable relative position of the  $\Delta I$  and  $\Delta F$  dose-response curves. Corelating the motions at the orthosteric site with known cryo-EM structures is, however, difficult. Indeed, two hypotheses can

be sustained by these results: the intermediate conformations revealed by these sensors can correspond either to those stabilized by setrons or to the pre-active conformations discussed above.

Altogether, VCF data highlight a progressive propagation of the signal following ligand binding. Setrons elicit local reorganizations shown by the sensors located around the orthosteric site, partial agonists elicit local reorganizations at the four sensors indicating a motion of the whole ECD with partial pore opening, and strong agonists elicit reorganizations detected by all four sensors together with channel opening. VCF data thus identify four families of conformations endowed with distinct  $\Delta I/\Delta F$  signatures contributing to signal transduction: resting-like apo, setron-inhibited, partial agonist-elicited pre-active and active states. The topological information given by the various sensors are remarkably consistent with the gallery of high-resolution structures solved thus far. Indeed, the data from fluorescence partners are consistent with respectively Apo, setron-bound, 5-HT bound-closed and 5-HT-bound open conformations. This provides important information allowing reasonable functional annotation of the various structures to physiological states in a membrane environment, at least regarding the ECD. Figure 4 shows a speculative four-state model as a framework integrating the whole set of data. In addition, VCF data give insights in the action of partial agonists, that do not exclusively stabilize the active state and document the phenotypes of various allosteric mutations.

A key observation of the study is the identification of pre-active intermediates that are favored upon binding of partial agonists and/or in the presence of loss-of-function mutations. It is noteworthy that single-channel kinetic analyses of pLGICs early showed that the activation transition pathway involves multiple intermediated states. Analysis of numerous mutants of the muscle nAChR analyzed by REFERS (rate equilibrium linear free energy relationships) suggested a multistep reorganization that initiates in the orthosteric site and progressively spreads to the ion channel gate (32). Analysis on GlyRs and nAChRs detected late intermediate-states called “flip” (33) or “primed” (34), that are favored by loss of function mutations (35,36), while a non-conducting intermediate state has been proposed from kinetic models of a high-conductance mutant of 5-HT<sub>3</sub>R(7).

More recently, fluorescence and VCF studies identified intermediate conformations for nAChRs,  $\alpha$ 1-GlyRs and the bacterial homolog GLIC(21,37–40). Of note, pre-active intermediates were unraveled by a fluorescence quenching pair at strictly homologous positions at the ECD-TMD interface of 5HT<sub>3</sub>R and  $\alpha$ 1-GlyRs. Indeed, residues R219C/Y140W are homologous to another sensor pair Q219C/K143W engineered on the  $\alpha$ 1-GlyR. MTS-TAMRA-labelled Q219C/K143W also reports a non-conducting intermediate in the pathway towards activation, with a fluorescence variation revealing an early reorganization of the ECD-TMD interface(21). Molecular dynamic simulations starting from a taurine-bound closed cryo-EM structure was found to recapitulate the pharmacological properties observed by VCF, suggesting that the intermediate conformations correspond to a highly dynamic family of conformations featuring an active-like ECD but a resting-like pore(41). Altogether, VCF shows that virtually all pLGICs appear to share a common global mechanism of gating where the proteins visit a family of structurally dynamic intermediates showing an active-like ECD and a resting-like TMD conformation. The present work thus expands this idea to the 5HT<sub>3A</sub>R, together with providing structural blueprints for cryo-EM structural annotation.

In conclusion, by monitoring simultaneously electrophysiologically silent and active conformations of the 5HT<sub>3</sub>R, VCF allowed to characterize the mechanisms of action of allosteric effectors and allosteric mutations. We found that the strength of the agonist correlated to a degree with

propagation of this fluorescence change beyond the local site of neurotransmitter binding, unraveling intermediate conformations allowing proposing a structure-based functional annotation of known high-resolution structures. Besides validating the mechanism underlying inhibition by setrons, these data unravel a unique mode of action of partial agonists to promote distinct intermediate conformations. The various fluorescence sensors developed will be valuable in future mutational analysis and characterization of drugs acting at the 5-HT<sub>3</sub>R that hold promise for clinical use.

## Materials and Methods

**Materials.** The ligands used for perfusion: 5-hydroxytryptamine hydrochloride (5-HT, serotonin), mCPBG, varenicline tartrate, alosetron, granisetron, ondansetron and metoclopramide have been purchased from Merck (Sigma). Hydrosoluble ligands were directly solubilized in distilled water or in recording solution, aliquoted at high concentrations, kept in -20°C and used freshly for dilution on the day of experiment. Less soluble ligands (ondansetron) were first dissolved in DMSO, aliquoted and kept at -20°C and then diluted in recording solutions at final concentrations not exceeding 1% of final DMSO on the day of experiment. The fluorescent dye MTS-TAMRA was purchased from Clinisciences, aliquoted in DMSO, kept at -20°C and freshly used for labelling.

**Site-directed mutagenesis.** All mutations were carried into the gene of the mouse 5-HT<sub>3A</sub> (described in Polovinkin et al., where strep-tags were removed), kindly provided by Hugues Nury (Institut de Biologie Structure, Grenoble, France) (9). The mutations were introduced by site-directed mutagenesis *via* PCR (CloneAmp Hifi, Takara). All mutations were assessed by complete sequencing of the gene (Eurofins Genomics). We have chosen to work with the mouse receptor because most of the available atomic structure have been obtained for m-5HT<sub>3A</sub> receptors.

**Oocytes handling.** *Xenopus laevis* ovarian fragments (TEFOR PARIS SACLAY CNRS UAR2010 / INRAE UMS1451) and dissociated stage VI oocytes (Ecocyte Biosciences, Germany) were used in the context of this study. Concerning ovarian fragments, oocytes were dissociated following enzymatic treatment with collagenase II (1 mg/mL; 1h at room temperature in gentle agitation) (ThermoFischer) in ORII solution (in mM: 82.5 NaCl, 2.5 KCl, 1 MgCl<sub>2</sub>, 5 HEPES, pH adjusted to 7.6 with NaOH). Selected oocytes were then handled in Barth's solution (in mM: 88 NaCl, 1 KCl, 0.33 Ca(NO<sub>3</sub>)<sub>2</sub>, 0.41 CaCl<sub>2</sub>, 0.82 MgSO<sub>4</sub>, 2.4 NaHCO<sub>3</sub>, 10 HEPES, pH adjusted to 7.6 with NaOH) at 18°C.

**cDNA injection.** cDNA encoding for m5-HT<sub>3A</sub> constructs were injected into the nucleus of oocytes (100ng) with cDNA encoding for eGFP as a reporter of correct injection (25ng) by an air injection system (Nanoject II, Drummond). Oocytes were then incubated at 18°C and used to be recorded 48 to 96 hours after injection.

**Labelling of mutants.** Oocytes were incubated for 20 minutes at room temperature with a solution containing 10 µM of MTS-TAMRA (in DMSO) and 1 to 10 µM of 5-HT (in ND96 0% calcium) allowing the final concentration of DMSO to not exceed 0.1%. The oocytes were then rinsed 3 times with perfusion solution and recorded during the following two hours.

**Voltage-clamp fluorometry.** Oocytes were placed in a custom-made recording chamber (described in Shi et al., 2023) (21). It allows to record and perfused the same part of the animal

pole that faces the perfusion and the inverted microscope. Oocytes were continuously perfused with freshly made ND96 0% Calcium (in mM: 96 NaCl, 2 KCl, 5 HEPES, 1 MgCl<sub>2</sub>, 1 HEPES, 1 EGTA and pH was adjusted at 7.6 with NaOH). To perform recordings, micro-electrodes (Borosilicate glass with filament BF150-110-7.5, WPI) of resistances comprised between 0.2 and 2 mΩ (pipette puller PC-10, Narishige) were used and oocytes were clamped at -60 mV for all the experiments. Recordings are performed with a GeneClamp 500 voltage patch-clamp amplifier (Axon Instruments) and a 1400 A digitizer (Axon Instruments) with Clampex 10.6 software (Molecular Devices). Recorded currents were sampled at 2kHz and filtered at 500Hz. The fluorescence emission was recorded via a FF01-543\_22 bandpass filter (Semrock) and collected by a photo-multiplier (H10722, Hamamatsu). The intensity of irradiation of the LEDs (pE-4000 CoolLED) and of the sensitivity of detection of the PMT were kept at the same level for all the experiments. For the screening experiment, 5-HT at 50 and 100 μM were perfused (around 10s). Dose-response curves of 5HT, mCPBG and varenicline were adapted to the phenotype of the construct (gain or loss-of-function) and used at concentrations stated in legends of graphs from the figures. Each concentration has been repeated twice for establishment of the dose-response curves. For the pharmacological experiments, used compounds were perfused on the same oocyte at saturating concentration (5-HT and mCPBG at 200 μM, varenicline at 400 μM, antagonists used have low nanomolar affinities and used here all at 3 μM concentration).

**Two electrode voltage-clamp.** Currents from impaled oocytes expressing m5-HT<sub>3A</sub> constructs were obtained under ND96 0% calcium perfusion. Currents were recorded by a Warner OC-725C amplifier and digitized by a Digidata 1550 A with Clampex 10 software (Molecular Devices). Currents were sampled at 500 Hz and filtered at 100 Hz. The voltage clamp is maintained at -60mV during all experiments. The TEVC setup has a faster perfusion than the VCF setup, as described in a previous paper from our lab (22). To characterize some of the desensitization properties, long application of 5-HT (45s) at several concentrations (10, 50, 100, 300 and 500 μM) have been applied to calculate the remaining currents after 45s application and compared to WT.

**Analysis of results.** Current and fluorescence analyses were made with Clampfit (Molecular Devices, Sunnyvale, CA). Dose response curves, EC<sub>50</sub> and Hill coefficients are obtained by the normalization of serotonin-induced currents to the maximal current followed by the fitting of the data by one-site Hill equation (GraphPad Prism). Error bars on figures represents +/- SEM. Results were obtained from at minima five different oocytes from at minima two different batches of oocytes. Rise time constants and desensitization constants have been calculated in Clampfit by mono-exponential fittings of signals. Statistical analyses have been made with Prism (unpaired t-tests).

## Acknowledgments

The work was supported by the ERC (Grant no. 788974, Dynacotine). The authors would like to thank Hugues Nury for the kind gift of the mouse 5-HT<sub>3</sub> cDNA, Kate Dunning, Solène Lefebvre and Thomas Grutter for the critical reading of the manuscript

## References

1. Nemezc Á, Prevost MS, Menny A, Corring PJ. Emerging Molecular Mechanisms of Signal Transduction in Pentameric Ligand-Gated Ion Channels. *Neuron*. mai 2016;90(3):452-70.


2. Gibbs E, Chakrapani S. Structure, Function and Physiology of 5-Hydroxytryptamine Receptors Subtype 3. *Subcell Biochem.* 2021;96:373-408.
3. Mawe GM, Hoffman JM. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. *Nat Rev Gastroenterol Hepatol.* août 2013;10(8):473-86.
4. Fakhfouri G, Rahimian R, Dyhrfeld-Johnsen J, Zirak MR, Beaulieu JM. 5-HT<sub>3</sub> Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface. *Pharmacol Rev.* juill 2019;71(3):383-412.
5. Tsitsipa E, Rogers J, Casalotti S, Belessiotis-Richards C, Zubko O, Weil RS, et al. Selective 5HT<sub>3</sub> antagonists and sensory processing: a systematic review. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol.* mars 2022;47(4):880-90.
6. Monod J, Wyman J, Changeux JP. On the nature of allosteric transitions: A plausible model. *J Mol Biol.* 1 mai 1965;12(1):88-118.
7. Corradi J, Gumilar F, Bouzat C. Single-channel kinetic analysis for activation and desensitization of homomeric 5-HT<sub>3</sub>A receptors. *Biophys J.* 2 sept 2009;97(5):1335-45.
8. Hassaine G, Deluz C, Grasso L, Wyss R, Tol MB, Hovius R, et al. X-ray structure of the mouse serotonin 5-HT<sub>3</sub> receptor. *Nature.* août 2014;512(7514):276-81.
9. Polovinkin L, Hassaine G, Perot J, Neumann E, Jensen AA, Lefebvre SN, et al. Conformational transitions of the serotonin 5-HT<sub>3</sub> receptor. *Nature.* nov 2018;563(7730):275-9.
10. Basak S, Gicheru Y, Samanta A, Molugu SK, Huang W, Fuente M la de, et al. Cryo-EM structure of 5-HT<sub>3</sub>A receptor in its resting conformation. *Nat Commun.* 6 févr 2018;9(1):514.
11. Basak S, Gicheru Y, Rao S, Sansom MSP, Chakrapani S. Cryo-EM reveals two distinct serotonin-bound conformations of full-length 5-HT<sub>3</sub>A receptor. *Nature.* nov 2018;563(7730):270-4.
12. Basak S, Gicheru Y, Kapoor A, Mayer ML, Filizola M, Chakrapani S. Molecular mechanism of setron-mediated inhibition of full-length 5-HT<sub>3</sub>A receptor. *Nat Commun.* 19 juill 2019;10(1):3225.
13. Basak S, Kumar A, Ramsey S, Gibbs E, Kapoor A, Filizola M, et al. High-resolution structures of multiple 5-HT<sub>3</sub>AR-setron complexes reveal a novel mechanism of competitive inhibition. Czajkowski CM, Boudker O, Czajkowski CM, éditeurs. *eLife.* 16 oct 2020;9:e57870.
14. Zarkadas E, Zhang H, Cai W, Effantin G, Perot J, Neyton J, et al. The Binding of Palonosetron and Other Antiemetic Drugs to the Serotonin 5-HT<sub>3</sub> Receptor. *Structure.* 6 oct 2020;28(10):1131-1140.e4.
15. Zhang Y, Dijkman PM, Zou R, Zandi-Lang M, Sanchez RM, Eckhardt-Strelau L, et al. Asymmetric opening of the homopentameric 5-HT<sub>3</sub>A serotonin receptor in lipid bilayers. *Nat Commun.* 16 févr 2021;12(1):1074.
16. Howard RJ. Elephants in the Dark: Insights and Incongruities in Pentameric Ligand-gated Ion Channel Models. *J Mol Biol.* 20 août 2021;433(17):167128.
17. Mannuzzu LM, Moronne MM, Isacoff EY. Direct Physical Measure of Conformational Rearrangement Underlying Potassium Channel Gating. *Science.* 12 janv 1996;271(5246):213-6.



18. Munro L, Ladefoged LK, Padmanathan V, Andersen S, Schiøtt B, Kristensen AS. Conformational Changes in the 5-HT<sub>3A</sub> Receptor Extracellular Domain Measured by Voltage-Clamp Fluorometry. *Mol Pharmacol.* déc 2019;96(6):720-34.
19. Mansoor SE, DeWitt MA, Farrens DL. Distance Mapping in Proteins Using Fluorescence Spectroscopy: The Tryptophan-Induced Quenching (TrIQ) Method. *Biochemistry.* 16 nov 2010;49(45):9722-31.
20. Beene DL, Price KL, Lester HA, Dougherty DA, Lummis SCR. Tyrosine Residues That Control Binding and Gating in the 5-Hydroxytryptamine<sub>3</sub> Receptor Revealed by Unnatural Amino Acid Mutagenesis. *J Neurosci.* 13 oct 2004;24(41):9097-104.
21. Shi S, Lefebvre SN, Peverini L, Cerdan AH, Milán Rodríguez P, Gielen M, et al. Illumination of a progressive allosteric mechanism mediating the glycine receptor activation. *Nat Commun.* 13 févr 2023;14(1):795.
22. Gielen M, Barilone N, Corringer PJ. The desensitization pathway of GABA<sub>A</sub> receptors, one subunit at a time. *Nat Commun.* 23 oct 2020;11(1):5369.
23. Kilpatrick GJ, Butler A, Burridge J, Oxford AW. 1-(m-chlorophenyl)-biguanide, a potent high affinity 5-HT<sub>3</sub> receptor agonist. *Eur J Pharmacol.* 21 juin 1990;182(1):193-7.
24. Lummis SCR, Thompson AJ, Bencherif M, Lester HA. Varenicline is a potent agonist of the human 5-hydroxytryptamine<sub>3</sub> receptor. *J Pharmacol Exp Ther.* oct 2011;339(1):125-31.
25. Price KL, Bower KS, Thompson AJ, Lester HA, Dougherty DA, Lummis SCR. A Hydrogen Bond in Loop A Is Critical for the Binding and Function of the 5-HT<sub>3</sub> Receptor. *Biochemistry.* 17 juin 2008;47(24):6370-7.
26. Sullivan NL, Sullivan NL, Thompson AJ, Price KL, Lummis SCR. Defining the roles of Asn-128, Glu-129 and Phe-130 in loop A of the 5-HT<sub>3</sub> receptor. *Mol Membr Biol.* 1 janv 2006;23(5):442-51.
27. Pless SA, Dibas MI, Lester HA, Lynch JW. Conformational variability of the glycine receptor M2 domain in response to activation by different agonists. *J Biol Chem.* 7 déc 2007;282(49):36057-67.
28. Pless SA, Lynch JW. Ligand-specific Conformational Changes in the  $\alpha$ 1 Glycine Receptor Ligand-binding Domain. *J Biol Chem.* 5 juin 2009;284(23):15847-56.
29. Pless SA, Lynch JW. Distinct conformational changes in activated agonist-bound and agonist-free glycine receptor subunits. *J Neurochem.* mars 2009;108(6):1585-94.
30. Han L, Talwar S, Lynch JW. The Relative Orientation of the TM3 and TM4 Domains Varies between  $\alpha$ 1 and  $\alpha$ 3 Glycine Receptors. *ACS Chem Neurosci.* 20 févr 2013;4(2):248-54.
31. Felt K, Stauffer M, Salas-Estrada L, Guzzo PR, Xie D, Huang J, et al. Structural basis for partial agonism in 5-HT<sub>3A</sub> receptors. *Nat Struct Mol Biol.* 4 janv 2024;1-12.
32. Grosman C, Zhou M, Auerbach A. Mapping the conformational wave of acetylcholine receptor channel gating. *Nature.* 17 févr 2000;403(6771):773-6.
33. Burzomato V, Beato M, Groot-Kormelink PJ, Colquhoun D, Sivilotti LG. Single-Channel Behavior of Heteromeric  $\alpha$ 1 $\beta$  Glycine Receptors: An Attempt to Detect a Conformational Change before the Channel Opens. *J Neurosci.* 1 déc 2004;24(48):10924-40.


34. Mukhtasimova N, Lee WY, Wang HL, Sine SM. Detection and trapping of intermediate states priming nicotinic receptor channel opening. *Nature*. 21 mai 2009;459(7245):451-4.
35. Plested AJR, Groot-Kormelink PJ, Colquhoun D, Sivilotti LG. Single-channel study of the spasmodic mutation alpha1A52S in recombinant rat glycine receptors. *J Physiol*. 15 mai 2007;581(Pt 1):51-73.
36. Lape R, Plested AJR, Moroni M, Colquhoun D, Sivilotti LG. The  $\alpha$ 1K276E Startle Disease Mutation Reveals Multiple Intermediate States in the Gating of Glycine Receptors. *J Neurosci*. 25 janv 2012;32(4):1336-52.
37. Dahan DS, Dibas MI, Petersson EJ, Auyeung VC, Chanda B, Bezanilla F, et al. A fluorophore attached to nicotinic acetylcholine receptor  $\beta$ M2 detects productive binding of agonist to the  $\alpha\delta$  site. *Proc Natl Acad Sci*. 6 juill 2004;101(27):10195-200.
38. Mouroto A, Bamberg E, Rettinger J. Agonist- and competitive antagonist-induced movement of loop 5 on the alpha subunit of the neuronal alpha4beta4 nicotinic acetylcholine receptor. *J Neurochem*. 1 avr 2008;105(2):413-24.
39. Menny A, Lefebvre SN, Schmidpeter PA, Drège E, Fourati Z, Delarue M, et al. Identification of a pre-active conformation of a pentameric channel receptor. *eLife*. 15 mars 2017;6:e23955.
40. Lefebvre SN, Taly A, Menny A, Medjebeur K, Corringer PJ. Mutational analysis to explore long-range allosteric couplings involved in a pentameric channel receptor pre-activation and activation. *eLife*. 30 sept 2021;10:e60682.
41. Yu J, Zhu H, Lape R, Greiner T, Du J, Lü W, et al. Mechanism of gating and partial agonist action in the glycine receptor. *Cell*. 18 févr 2021;184(4):957-968.e21.

## Figures and Tables




**Figure 1. Screening of residues located along the extracellular domain (ECD) of m5-HT<sub>3</sub>AR as potential anchors for fluorescent probes and establishment of four reporter sensors. A.** Left panel: visualization of the residues mutated, TAMRA-labelled and tested for variation of current and fluorescence on the Apo Cryo-EM structure of m5-HT<sub>3A</sub> (from Basak et al., 2018), in lateral (zoom on the ECD) and top view with two subunits in cartoon representation and the three others represented in surface mode (PDB: 6BE1). Middle panel: representation of the two isomers of the labeling fluorescent probe mixture used in this study, MTS-TAMRA (5(6)-carboxytetramethylrhodamine methanethiosulfonate). Right panel: representation of currents evoked by 50-100  $\mu$ M of 5-HT on the mutants and of the absolute values of variation of fluorescence (difference between the baseline fluorescence and steady-state fluorescence upon 5-HT perfusion) recorded simultaneously. Note the representation of the four selected sensors: in dark green,

I160C/Y207W; in magenta, S204C; in purple, V106C/L131W and in cyan, R219C/Y140W. **B.** The sensor S204C, shown on 5-HT bound conformation (5-HT represented in red; PDB: 6DG8), is located on loop C. Note that the fluorescence variation is significantly increased by the addition of the tryptophan in the sensors I160C/Y207W and V106C/L131W. (unpaired t-tests, I160C/Y207W versus I160C P value = 0,013 (\*); V106C/L131W versus V106C P value = 0,0081 (\*\*)) **C.** The sensor I160C/Y207W where I160C is the point of labelling with MTS-TAMRA and is represented in ball representation in fluorescent green, Y207 is mutated into tryptophan and colored in dark green. **D.** The sensor V106C/L131W where V106C is represented in ball representation in purple and L131 is mutated into tryptophan and colored in purple. Note the vestibular positioning of this sensor. **E.** The sensor R219C/Y140W, where R219C, located in pre-M1 loop, is represented in ball representation in cyan and Y140, located in the Cys-loop, is mutated into tryptophan, and colored in dark cyan. **F.** Molecular structures of the ligands used in this study: agonists (in red, 5-HT; in blue, mCPBG; in salmon, varenicline) and antagonists (all represented in orange, A: alosetron, G: granisetron, O: ondansetron, M: metoclopramide). **G.** Effect of desensitization on the dynamic of the fluorescence recordings. Examples of desensitizing currents promoted by long mCPBG (perfused on the sensor I160C/Y207W) or 5-HT application (perfused on the sensors S204C, V106C/L131W and R219C/Y140W), showing that the fluorescent signal remains stable during desensitization for all the sensors. Note that the differences in the desensitization kinetics of the displayed traces are due to the variability of different oocyte batches, since the four conditions do not show significant differences in desensitization kinetics (Fig S2).



**Figure 2. Electrophysiological and fluorescence characterization of S204C and I160C/Y207W, two sensors located in proximity to the ligand-binding site. A. Exploration and characterization of the sensor S204C.** Left upper panel: macroscopic ligand-gated currents (in black) and fluorescence (in magenta) recorded at  $-60\text{mV}$  on S204C labelled with MTS-TAMRA evoked by saturating concentrations of agonists (in red, 5-HT,  $200\mu\text{M}$ ; in blue, mCPBG,  $200\mu\text{M}$ ; in salmon, varenicline,  $400\mu\text{M}$ ) and antagonists (all represented in orange, A: alosetron, G: granisetron, O: ondansetron, M: metoclopramide, all at  $3\mu\text{M}$ ). Left bottom panel: graphical representation of ligand-induced relative changes of current and fluorescence compared to 5-HT. The normalized values for all the ligands are compared with the mean values obtained for 5-HT. Middle left top panel: representative recording of current and fluorescence variations of S204C labelled with MTS-TAMRA upon different concentrations of perfused 5-HT. Middle left bottom panel: dose-response curves for  $\Delta I$  (black) and  $\Delta F$  (magenta) with mean and SEM (normalized by the maximum current of each oocytes) for application of 5-HT. Middle right top panel: representative


recording of current and fluorescence variations of S204C labelled with MTS-TAMRA upon different concentrations of perfused mCPBG. Middle right bottom panel: dose-response curves for  $\Delta I$  (black) and  $\Delta F$  (magenta) for application of mCPBG. Right top panel: representative recording of current and fluorescence variations of S204C labelled with MTS-TAMRA upon different concentrations of perfused varenicline. Right bottom panel: dose-response curves for  $\Delta I$  (black) and  $\Delta F$  (magenta) for application of varenicline. **B. Effect of loss-of-function mutation N101K on the sensor S204C.** Same experiments and legends as for panel A. but the construct here is the sensor S204C with the additional loss-of-function mutation N101K. **C. Exploration and characterization of the sensor I160C/Y207W.** Same experiments and legends as for panel A, but here currents are represented in black and fluorescence in green. Note also than for the left lower panel, currents and fluorescence have been compared to mCPBG instead of 5-HT.



**Figure 3. Electrophysiological and fluorescence characterization of V106C/L131W, located in the extracellular vestibular area and R219C/Y140W positioned at the interface area between ECD and TMD. A. Exploration and characterization of the sensor V106C/L131W.** Left top panel: macroscopic ligand-gated currents (in black) and fluorescence (in purple) recorded at -60mV on the construct with the sensor V106C/L131W labelled with MTS-TAMRA evoked by saturating concentrations of agonists (in red, 5-HT; in blue, mCPBG; in salmon, varenicline) and antagonists (all represented in orange, A: alosetron, G: granisetron, O: ondansetron, M: metoclopramide). Left bottom panel: graphical representation of ligand-induced relative changes of

current and fluorescence compared to 5-HT. The normalized values for all the ligands are compared with the mean values obtained for 5-HT. Middle top panel: representative recording of current and fluorescence variations of V106C/L131W labelled with MTS-TAMRA upon different concentrations of perfused 5-HT. Middle bottom panel: dose-response curves for  $\Delta I$  (black) and  $\Delta F$  (purple) with mean and SEM (normalized by the maximum current of each oocytes) for application of 5-HT. Right top panel: representative recording of current and fluorescence variations of V106C/L131W labelled with MTS-TAMRA upon different concentrations of perfused varenicline. Right bottom panel: dose-response curves for  $\Delta I$  (black) and  $\Delta F$  (magenta) with mean and SEM (normalized by the maximum current of each oocytes) for application of varenicline. **B. Exploration and characterization of the sensor R219C/Y140W** Same experiments and legends as for the panel A. but the construct here is the sensor R219C/Y140W, current is represented in black and fluorescence in cyan (in trace recordings and dose-response representations). **C. Effect of loss-of-function mutation N101K on the sensor R219C/Y140W.** Same experiments and legends as for the panel A. but the construct here is the sensor R219C/Y140W with the additional loss-of-function mutation N101K, current is represented in black and fluorescence in cyan (in trace recordings and dose-response representations).





**Figure 4. Hypothetical integrative model of VCF data.** Schematic representation of the 5-HT<sub>3</sub>R representing two subunits in side-view with the orthosteric site and ion channel M2 helices highlighted. The four fluorescent sensors are represented as hexagons following the color code of figure 1 (S204C in magenta, I160C/Y207W in green, V106C/L131W in purple, R219C/Y140W in cyan). Ligand-elicited fluorescence changes are represented as a light halo. VCF data identifies four different conformations whose fluorescence patterns match known high-resolution structures. These conformations are called resting (matching apo structures, PDB 4PIR, 6BE1, 6H5B, 6Y59), inhibited (matching setron-bound structures, PDB 6HIS, 6W1J, 6W1M, 6W1Y, 6Y1Z), intermediate (matching I1 and state1, PDB 6HIO, 6DG7) and active (matching F, state2, and open, PDB 6HIN, 6DG8, 6Y5A).

**Table 1:** Current and fluorescence maximum evoked by ligands (agonist and antagonists) on m5-HT<sub>3A</sub> mutants

Construct	Molecule	$\Delta I_{max_{molecule}}$ compared to $\Delta I_{max_{5-HT}}$ +/- SEM	$\Delta F_{max_{molecule}}$ compared to $\Delta F_{max_{5-HT}}$ +/- SEM	<i>n</i>
<b>Wild-type</b>	mCPBG	0.92 +/- 0.03	/	6
	Varenicline	0.39 +/- 0.06	/	
	alosepron	0	/	
	granisetron	0	/	
	ondasetron	0	/	
	metoclopramide	0	/	
<b>S204C + MTS-TAMRA</b>	mCPBG	0.89 +/- 0.04	1.09 +/- 0.105	6
	Varenicline	0.33 +/- 0.06	1.12 +/- 0.16	
	alosepron	0	1.44 +/- 0.20	
	granisetron	0	1.14 +/- 0.19	
	ondasetron	0	0.78 +/- 0.13	
	metoclopramide	0	0.52 +/- 0.08	
<b>I160C/Y207W + MTS-TAMRA</b>	mCPBG	*5-HT - 0.02 +/- 0.004	1.21 +/- 0.06	8
	Varenicline	*0	1.52 +/- 0.06	
	alosepron	*0	2.26 +/- 0.10	
	granisetron	*0	1.12 +/- 0.07	
	ondasetron	*0	1.27 +/- 0.03	
	metoclopramide	*0	0.60 +/- 0.04	
<b>V106C/L131W + MTS-TAMRA</b>	mCPBG	0.64 +/- 0.06	0.93 +/- 0.06	6
	Varenicline	0.33 +/- 0.04	0.49 +/- 0.06	
	alosepron	0	0	
	granisetron	0	0	
	ondasetron	0	0	
	metoclopramide	0	0	
<b>R219C/Y140W + MTS-TAMRA</b>	mCPBG	0.62 +/- 0.07	0.94 +/- 0.09	6
	Varenicline	0.34 +/- 0.08	0.47 +/- 0.02	
	alosepron	0	0	
	granisetron	0	0	
	ondasetron	0	0	
	metoclopramide	0	0	
<b>S204C + N101K - MTS-TAMRA</b>	mCPBG	1.80 +/- 0.11	1.23 +/- 0.05	8
	Varenicline	0	1.73 +/- 0.05	
<b>R219C/Y140W + N101K - MTS-TAMRA</b>	mCPBG	0.83 +/- 0.08	1.20 +/- 0.08	7
	Varenicline	0.03 +/- 0.01	0.38 +/- 0.06	

**Table 2:** EC<sub>50</sub> values for current (EC<sub>50c</sub>) and fluorescence (EC<sub>50f</sub>) responses to agonists (5-HT, mCPBG, varenicline) at labeled and unlabeled m5-HT<sub>3A</sub> mutants. The top part of the table represents the characterization of the sensors with different ligands and the associated controls (rows 1 to 13) and the second part the additional allosteric mutations added (rows 14 to 16).

Construct	Molecule	EC <sub>50c</sub> (μM) +/- SEM	n <sub>HillC</sub> +/- SEM	EC <sub>50f</sub> (μM) +/- SEM	n <sub>Hillf</sub> +/- SEM	n
Wild-type (WT)	5-HT	1.83 +/- 0.12	1.74 +/- 0.13	/	/	8
	mCPBG	1.13 +/- 0.15	1.02 +/- 0.14	/	/	6
	Varenicline	21.09 +/- 1.03	1.595 +/- 0.07	/	/	5
WT + MTS-TAMRA	5-HT	3.43 +/- 0.24	1.98 +/- 0.12	/	/	5
I160C/Y207W + MTS-TAMRA	5-HT	31.22 +/- 2.76	1.69 +/- 0.18	10.73 +/- 0.62	1.56 +/- 0.14	7
	mCPBG	7.99 +/- 0.58	1.19 +/- 0.105	7.46 +/- 0.755	0.92 +/- 0.08	8
	Varenicline	No current	/	16.80 +/- 0.76	1.29 +/- 0.06	7
I160C/Y207W unlabelled	5-HT	47.33 +/- 4.72	1.19 +/- 0.135	/	/	6
	mCPBG	2.73 +/- 0.17	1.59 +/- 0.11	/	/	8
	Varenicline	No current	/	/	/	/
I160C + MTS-TAMRA	5-HT	31.01 +/- 1.64	1.73 +/- 0.11	/	/	5
S204C + MTS-TAMRA	5-HT	1.78 +/- 0.13	1.39 +/- 0.11	2.86 +/- 0.248	1.51 +/- 0.14	6
	mCPBG	1.45 +/- 0.18	0.94 +/- 0.10	2.90 +/- 0.40	0.80 +/- 0.08	6
	Varenicline	20.67 +/- 0.705	1.48 +/- 0.05	16.31 +/- 0.78	1.29 +/- 0.06	7
S204C unlabelled	5-HT	1.93 +/- 0.25	1.08 +/- 0.12	/	/	6
	mCPBG	0.54 +/- 0.02	1.94 +/- 0.16	/	/	6
	Varenicline	17.105 +/- 1.12	1.385 +/- 0.07	/	/	7
V106C/L131W + MTS-TAMRA	5-HT	1.25 +/- 0.155	0.84 +/- 0.08	0.88 +/- 0.16	0.68 +/- 0.08	5
	Varenicline	7.745 +/- 0.775	0.80 +/- 0.05	2.33 +/- 0.45	0.60 +/- 0.06	5
V106C/L131W unlabelled	5-HT	1.91 +/- 0.17	0.99 +/- 0.07	/	/	9
	Varenicline	6.06 +/- 0.32	1.47 +/- 0.12	/	/	5
V106C + MTS-TAMRA	5-HT	4.47 +/- 0.55	1.08 +/- 0.13	/	/	5
R219C/Y140W + MTS-TAMRA	5-HT	0.33 +/- 0.05	0.82 +/- 0.10	0.47 +/- 0.07	0.71 +/- 0.07	8
	Varenicline	0.94 +/- 0.12	0.77 +/- 0.08	0.96 +/- 0.19	0.68 +/- 0.10	6
R219C/Y140W unlabelled	5-HT	0.60 +/- 0.01	0.94 +/- 0.10	/	/	7
	Varenicline	1.575 +/- 0.28	0.875 +/- 0.12	/	/	6
R219C + MTS-TAMRA	5-HT	0.11 +/- 0.03	0.92 +/- 0.21	0.185 +/- 0.04	0.94 +/- 0.15	6
WT + N101K	5-HT	66.67 +/- 3.11	1.95 +/- 0.185	/	/	6
S204C + N101K	5-HT	57.11 +/- 1.49	2.33 +/- 0.17	12.19 +/- 0.90	1.285 +/- 0.11	6
	varenicline	No current	/	25.30 +/- 2.46	0.94 +/- 0.07	7
	mCPBG	13.10 +/- 0.79	1.345 +/- 0.10	4.365 +/- 0.495	0.72 +/- 0.05	7
R219C/Y140W + N101K	5-HT	3.32 +/- 0.39	0.94 +/- 0.10	1.62 +/- 0.27	0.86 +/- 0.11	9
	varenicline	15.65 +/- 2.70	0.76 +/- 0.09	5.25 +/- 0.95	0.69 +/- 0.07	6